Akebia Therapeutics Files 8-K

TL;DR

AKBA filed an 8-K on 10/28/25 covering Reg FD, other events, and financials.

AI Summary

Akebia Therapeutics, Inc. filed an 8-K on October 28, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Cambridge, Massachusetts.

Why It Matters

This 8-K filing provides updates on Akebia Therapeutics' corporate activities and financial reporting, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news or events.

Key Numbers

• 001-36352 — SEC File Number (Identifies the company's filing with the SEC.)
• 20-8756903 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Akebia Therapeutics, Inc. (company) — Registrant
• October 28, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Cambridge, Massachusetts (location) — Principal Executive Offices
• 245 First Street (address) — Business Address

FAQ

Key Financial Figures

• $0.00001 — ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital Marke

Filing Documents

• akba-20251028.htm (8-K) — 35KB
• regulatoryupdate_10282025x.htm (EX-99.1) — 34KB
• 0001517022-25-000040.txt ( ) — 205KB
• akba-20251028.xsd (EX-101.SCH) — 2KB
• akba-20251028_def.xml (EX-101.DEF) — 4KB
• akba-20251028_lab.xml (EX-101.LAB) — 24KB
• akba-20251028_pre.xml (EX-101.PRE) — 14KB
• akba-20251028_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On October 28, 2025, Akebia Therapeutics, Inc. (the "Company") issued a press release announcing that after meeting with the U.S. Food and Drug Administration ("FDA"), it has not come to alignment on a path forward for the design of the VALOR clinical trial for the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease ("CKD") not on dialysis. As a result, the Company does not plan to initiate VALOR and therefore does not expect to pursue a broad label for Vafseo for CKD non-dialysis dependent patients. A copy of the Company's press release containing this information is attached as Exhibit 99.1 to this Current Report on Form 8-K ("Report") and is incorporated herein by reference. The information in Item 7.01 of this Report (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

01. Other Events

Item 8.01. Other Events. On October 28, 2025, the Company announced that after meeting with the FDA, it has not come to alignment on a path forward for the design of the VALOR clinical trial for the use of vadadustat to treat anemia in patients with late-stage CKD not on dialysis. As a result, the Company does not plan to initiate VALOR and therefore does not expect to pursue a broad label for Vafseo for CKD non-dialysis dependent patients.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 28, 202 5 , issued by Akebia Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Note Regarding Forward-Looking Statements This Report contains forward-looking statements of the Company that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Report are forward-looking statements. The words "anticipate," "believe," "build," "can," "contemplate," "continue," "could," "should," "designed," "estimate," "project," "expect," "forecast," "future," "goal," "intend," "likely," "may," "plan," "possible," "potential," "predict," "strategy," "seek," "target," "will," "would," derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements relating to the Company's plans to not initiate the VALOR clinical trial and that the Company therefore does not expect to pursue a broad label for Vafseo for CKD non-dialysis dependent patients. Actual results may differ materially from those projected or implied in these forward-looking statements. You should not place undue reliance on these forward-looking statements. Certain risks and uncertainties relating to the Company and its business can be found under the caption "Risk Factors" included in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and other filings that the Company may make with the U.S. Securities and Exchange Commission in the future. Any forward-looking statements contained in this Report (except as otherwise noted) speak only as of the date hereof, and, except as required by law, the Company does not undertake, and specifically disclaims, any obligation

View Full Filing

View this 8-K filing on SEC EDGAR